Evidence map›Paper›PMID 36084494›Full record

ArticleSleep medicine2022

Effects of solriamfetol treatment on body weight in participants with obstructive sleep apnea or narcolepsy.

Atul Malhotra, Patrick J Strollo, Jean-Louis Pepin, Paula Schweitzer, Gert Jan Lammers, Jan Hedner, Susan Redline, Dan Chen, Patricia Chandler, Shay Bujanover and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Sleep medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 4 countries.

Atul MalhotraDivision of Pulmonary, Critical Care and Sleep Medicine, University of California San Diego Medical Center, La Jolla, CA, USA. Electronic address: amalhotra@ucsd.edu.
Patrick J StrolloUniversity of Pittsburgh/Veterans Administration Pittsburgh Health System, Pittsburgh, PA, USA.
Jean-Louis PepinUniversité Grenoble Alpes, INSERM U1300, CHU Grenoble Alpes, HP2, 38000, Grenoble, France.
Paula SchweitzerSleep Medicine and Research Center, St. Luke's Hospital, Chesterfield, MO, USA.
Gert Jan LammersSleep-Wake Centre SEIN, Netherlands; Department of Neurology, Leiden University Medical Centre, Leiden, Netherlands.
Jan HednerSahlgrenska University Hospital, Gothenburg University, Gothenburg, Sweden.
Susan RedlineBrigham and Women's Hospital, Harvard University, Boston, MA, USA.
Dan ChenJazz Pharmaceuticals, Palo Alto, CA, USA.
Patricia ChandlerJazz Pharmaceuticals, Palo Alto, CA, USA.
Shay BujanoverJazz Pharmaceuticals, Palo Alto, CA, USA.
Kingman StrohlCase Western Reserve University, Cleveland, OH, USA.
Jazz Pharmaceuticals (United States) · USBrigham and Women's Hospital · USCase Western Reserve University · USInserm · FRLeiden University Medical Center · NLSahlgrenska University Hospital · SESt. Luke's Hospital · USUniversity of California San Diego · USUniversity of Pittsburgh · US

Funding

Is Obstructive Sleep Apnea Important in the Development of Alzheimer's DiseaseR01AG063925 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MALHOTRA, ATUL · 2020 to 2024
$3.7M
Underlying mechanisms of obesity-induced obstructive sleep apneaR01HL148436 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Atul Malhotra · 2020 to 2026
$3.4M
Sleep Apnea Endophenotypes: One Size Does Not Fit AllR01HL154926 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MALHOTRA, ATUL · 2021 to 2025
$3.3M
VentNet: A Real-Time Multimodal Data Integration Model for Prediction of Respiratory Failure in Patients with COVID-19R01HL157985 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MALHOTRA, ATUL, NEMATI, SHAMIM · 2022 to 2025
$2.9M
Training in the Next Generation in Respiratory ScienceT32HL134632 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MALHOTRA, ATUL, POWELL, FRANK L. · 2017 to 2021
$2.1M
Assessment of Upper Airway Mechanics Using Newer Electromyographic TechniquesK24HL132105 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MALHOTRA, ATUL · 2016 to 2020
$611k
NHLBI NIH HHS K24 HL132105NHLBI NIH HHS R01 HL148436NHLBI NIH HHS R01 HL154926NHLBI NIH HHS R01 HL157985NHLBI NIH HHS T32 HL134632NIA NIH HHS R01 AG063925
6 · The paper itself

Abstract

objectivesThis analysis characterized changes in weight in participants with obstructive sleep apnea (OSA) or narcolepsy treated with solriamfetol (Sunosi™) 37.5 (OSA only), 75, 150, or 300 mg/d.

methodsIn two 12-week, randomized, placebo-controlled trials and one 1-year open-label extension study, changes in weight were evaluated from baseline to end of study (week 12 or week 40 of the open-label extension [after up to 52 weeks of solriamfetol treatment]) in participants with OSA or narcolepsy.

resultsAfter 12 weeks of solriamfetol treatment, median percent change in weight from baseline across all solriamfetol doses was -0.84%, compared with 0.54% for placebo, in participants with OSA; and -0.07%, compared with 3.08% for placebo, in participants with narcolepsy. After up to 52 weeks of solriamfetol treatment, overall median percent change in weight from baseline was -1.76%, which showed a dose-dependent pattern (75 mg, 0.57%; 150 mg, -1.2%; 300 mg, -2.5%). Results were similar in subgroups of participants with OSA or narcolepsy, with overall median percent changes in weight of -2.2% and -1.1%, respectively. After up to 52 weeks of solriamfetol treatment, the percentage of participants with weight loss ≥5% relative to baseline was 25.7% overall and increased in a dose-dependent manner (75 mg, 4.5%; 150 mg, 17.3%; 300 mg, 32.4%). Results were similar among subgroups of participants with OSA or narcolepsy, with 26.4% and 24.2% of participants experiencing weight loss ≥5%, respectively. No weight-related treatment-emergent adverse events were serious.

conclusionsSolriamfetol treatment was associated with decreases in body weight in a dose-related manner.

Indexed as

NarcolepsySleep Apnea, ObstructiveBody WeightCarbamatesHumansPhenylalanineWeight LossCarbamatesPhenylalaninesolriamfetolJZP-110LungObesitySleep apneaSolriamfetolSunosi

Identifiers

PMID36084494
PMCPMC9669231
OpenAlexW4291298099

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.